<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Altered regulation of oncogene expression has been described in a variety of <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study we analyzed the protein level of c-myc and c-myb in 15 established cell lines derived from lymphopoietic disorders and in 45 samples from patients with <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0005550'>chronic lymphatic leukemias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Oncoproteins were assayed by radioimmuno-precipitation with polyclonal rabbit antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>In B-cell derived lines, such as Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0032131" disease_type="Neoplastic Process" abbrv="">plasmocytoma</z:e> lines, we found high amounts of c-myc and no or low amounts of c-myb </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, <z:hpo ids='HP_0000001'>all</z:hpo> T-cell-derived lines revealed high levels of c-myb </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, T-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines of low <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> also exhibited high levels of c-myc, while T-cell lines of high <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> (<z:hpo ids='HP_0011009'>acute</z:hpo> T-lymphoblastic <z:hpo ids='HP_0001909'>leukemias</z:hpo>) exhibited moderate levels of c-myc </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 45 patient samples analyzed, only three (one B-prolymphocytic and two <z:hpo ids='HP_0011009'>acute</z:hpo> T-lymphoblastic <z:hpo ids='HP_0001909'>leukemias</z:hpo>) contained detectable amounts of myc or myb protein </plain></SENT>
<SENT sid="7" pm="."><plain>Corresponding to the results found in established cell lines, the B-cell sample revealed a high level of c-myc but no c-myb, while the T-cell samples revealed high levels of c-myb and no or low levels of c-myc </plain></SENT>
<SENT sid="8" pm="."><plain>We therefore conclude that the predominance of c-myc or c-myb expression in malignant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> may be associated to the B-cell or T-cell lineage, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Further, regarding the T-cell lines, there is a possible correlation between cell maturation and the level of c-myc found together with a consistently elevated c-myb </plain></SENT>
</text></document>